Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Caliper Technologies Corp

This article was originally published in The Gray Sheet

Executive Summary

Initial public offering of 4.5 mil. shares at $16 each grosses $72 mil. Larger than the previously anticipated 3.6 mil. shares at $13-15 each, the IPO will help fund scale-up of manufacturing operations for initial LabChip "lab-on-a-chip" technologies and further R&D activities (1"The Gray Sheet" Dec. 6, p. 16). The Mountain View, California firm's stock is trading under the symbol "CALP," and not "CLPR" as expected earlier. Credit Suisse First Boston, CIBC World Markets Corp. and Hambrecht & Quist LLC were underwriters for the offering

You may also be interested in...



Caliper's $46 Mil. IPO To Fund LabChip Manufacturing Scale-Up, R&D

Development of "lab-on-a-chip" technologies used in high-throughput nucleic acid analysis for diagnostics applications is one of several development projects that would benefit from Caliper Technologies' $46 mil. initial public offering.

Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients

As China Rushes Medical Supplies To World, Quality Issues Resurface

As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.

UsernamePublicRestriction

Register

MT012721

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel